Eli Lilly Reports Phase 3 TRANSCEND-T2D-2 Results, With Retatrutide Achieving Greater A1C Reduction And Weight Loss Than Ozempic In Adults With Type 2 Diabetes
In adults with type 2 diabetes, retatrutide lowered A1C by an average of 2.2% vs. 1.8% with Ozempic 2 mg at 80 weeksParticipants taking retatrutide lost an average of 44 lbs to 47 lbs (20% to 21%) vs. 21 lbs (9%) with
Eli Lilly's new diabetes drug worked better than a popular competitor in testing. When comparing two medicines, the one that works better often means the company may do well.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.